Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.

Saved in:
Bibliographic Details
Title: Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.
Authors: Ontiveros-Padilla L; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Hendy DA; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Pena ES; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; Department of Biomedical Engineering, North Carolina State University and University of North Carolina, Chapel Hill, NC, USA., Williamson GL; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Murphy CT; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Lukesh NR; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Ashcraft KA; Department of Pathology, School of Medicine, Duke University, Durham, NC, United States., Abraham MA; Department of Pathology, School of Medicine, Duke University, Durham, NC, United States., Landon CD; Department of Pathology, School of Medicine, Duke University, Durham, NC, United States., Staats HF; Department of Pathology, School of Medicine, Duke University, Durham, NC, United States; Duke Human Vaccines Institute, School of Medicine, Duke University, Durham, NC, United States., Abraham SN; Departments of Pathology, Molecular Genetics and Microbiology and Immunology, Duke University School of Medicine, Durham, NC, United States., Carlock M; Florida Research and Innovation Center, Port Saint, Cleveland Clinic Florida, Port St. Lucie, FL, USA; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Ross TM; Florida Research and Innovation Center, Port Saint, Cleveland Clinic Florida, Port St. Lucie, FL, USA; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Petrovsky N; School of Medicine, Faculty of Medicine, Nursing and Health Sciences, Flinders University, Adelaide, SA 5042, Australia; Vaxine Pty Ltd, 1 Flinders Lane, Bedford Park, Adelaide, SA 5042, Australia., Heise MT; Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, USA., Bachelder EM; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Ainslie KM; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; Department of Biomedical Engineering, North Carolina State University and University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ainsliek@email.unc.edu.
Source: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Aug 10; Vol. 384, pp. 113855. Date of Electronic Publication: 2025 May 18.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-4995
DOI:10.1016/j.jconrel.2025.113855